Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Nirsevimab for prevention of Respiratory Syncytial Virus (RSV)
Scheduled Substance Treatment Protocol
Revocation and Approval

I, Christine Maree Connors, Chief Health Officer:

(a) under section 254(5) of the *Medicines, Poisons and Therapeutic Goods Act 2012, (**the Act**),* revoke the instrument titled "Nirsevimab for Maternity Services SSTP Approval" dated 31 October 2024; and

(b) under section 254(1) of the Act, approve each Scheduled substance treatment protocol specified in Schedule A;

(c) under section 254(3) of the Act, state that each Schedule substance treatment protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this instrument.

Dated

31/01/2025 **EDOC2025/22982**

Chief Health Officer

Schedule A

Title	Publication Date	Author
Nirsevimab Scheduled Substance Treatment Protocol (SSTP) V2	29 January 2025	Immunisation – Public Health Directorate, Northern Territory Government, Department of Health

Scheduled Substance Treatment Protocol

Nirsevimab Scheduled Substance Treatment Protocol (SSTP) V2

Areas Applicable	NT Wide
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners
Scheduled Substance(s)	Nirsevimab
Indication	For the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract infection as per the current version of the Australian Immunisation Handbook
Contraindications and/or Exclusions	As per contraindications listed in the current Australian Immunisation Handbook and individual vaccine product information
Dose and Route	Dose and route as per Australian Immunisation Handbook
Administration	Intramuscular
Dose Frequency	Dose frequency as per the Australian Immunisation Handbook.
Drug Interactions	Drug interactions as per the Australian Immunisation Handbook.
Monitoring requirements	Post vaccination procedures should be followed as per the Australian Immunisation Handbook. All patients must be monitored post vaccination for 15 minutes unless they withdraw consent to be monitored. Ensure withdrawn consent is documented in the person's clinical record. Report any adverse event during or post vaccination to the NT Centre for Disease Control using the 'Adverse event following vaccination' form available online https://health.nt.gov.au/professionals/centre-for-diseasecontrol/immunisation-program
Health Professional Accreditation Requirements	Health professionals using this guideline must meet the requirements outlined by the NT Chief Health Officer: **Nurses and Midwives:**

NORTHERN TERRITORY GOVERNMENT

	• Be registered with the Nursing and Midwifery Board of Australia with no conditions, undertakings or notations which may limit delivery of clinical services directly to patients **Aboriginal Health Practitioners:** • Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients. **All health professionals following this protocol must:** • Maintain continuing professional development related to skills and competencies required for the delivery of medicines and vaccines including the use of multi-dose vials and management of anaphylaxis • Hold a current Cardiopulmonary Resuscitation (CPR) certificate **All health professionals administering vaccines from this protocol must have completed and hold a current qualification in:** • A program of study accredited by Health Education Services Australia (HESA) or; • A program of study approved by the Chief Health Officer or; • Completed the assessment of an immuniser program of study that meets the curriculum content requirements of the National Immunisation Education Framework for Health Professionals
Documentation *(including necessary information to the patient)*	Patient consent (written or verbal) for vaccination must be recorded. Records of this should be maintained by the clinical service. The health professional must: • Complete all clinical documentation requirements as outlined by the Health Service. • Enter the mandatory fields in the Australian Immunisation Register within 24 hours and no later than 10 days after administration. For many vaccine providers this involves entry into routine clinical information systems for automatic upload
Related Documents	• The Australian Immunisation Handbook (health.gov.au) • National vaccine storage guidelines - Strive for 5, 3rd edition (health.gov.au) • ASCIA_HP_Guidelines_Acute_Management_Anaphylaxis_2023.pdf (allergy.org.au) Immunisation program | NT Health Australian product information beyfortus™ (nirsevimab) solution for injection (https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-02637-1)

Chief Health Officer	**Signature**	**Name**	**Date**
	EDOC2025/22974	Dr Christine Connors	31/01/2025

		Chief Health Officer	
Period of effect	This SSTP is in force until 31/01/2027 unless revoked earlier		

References:

* The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration